IL17A and psoriasis: In this study, we investigated the hypothesis that psoriasis disease severity, as reflected by the level and change in the Psoriasis Area Severity Index (PASI) score, is associated with serum urate levels in the context of data collected in three large, pivotal randomized control trials of secukinumab, an IL-17A inhibitor, for psoriasis.